News & Updates

Despite reducing triglyceride levels, pemafibrate does not reduce the risk of cardiovascular (CV) events among patients with type 2 diabetes (T2D) and hypertriglyceridemia, according to results of the PROMINENT trial presented at AHA 2022.

Individuals with symptoms of psychological distress are at increased risk of all-cause dementia, although this association is attenuated by the competing risk of death, according to a study.

In the subgroup analysis of the HERO trial, the first-in-class oral, highly selective, GnRH* antagonist relugolix was effective and well tolerated in Asian men with advanced prostate cancer.

The serine protease inhibitor upamostat appears to be beneficial in the treatment of COVID-19 outpatients, being generally tolerable and bringing a rapid resolution of severe symptoms while reducing the incidence of new ones, according to the results of a pilot study.

For individuals with obesity who are scheduled to undergo bariatric surgery, faecal microbiota transplantation (FMT) from a lean donor does not appear to help reduce weight before or after the procedure, according to a study.

In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).